EY3238
| Code | Size | Price |
|---|
| TAR-T27298-5mg | 5mg | £1,167.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
EY3238 is an inhibitor of JAK2, HDAC2, HDAC6 and HDAC10 (JAK2 IC50 = 1.4 nM; HDAC2 IC50 = 49nM; HDAC6 IC50 = 2.1 nM; HDAC10 IC50 = 80 nM).
CAS:
1995861-12-5
Formula:
C29H34N4O5
Molecular Weight:
518.614
Purity:
0.98
SMILES:
ONC(=O)CCCCCCOc1ccc2Nc3nccc(n3)-c3cccc(COCC=CCOCc1c2)c3
References
1. Yang, E. G.; Mustafa, N.; Tan, E. C.; Poulsen, A.; Ramanujulu, P. M.; Chng, W. J.; Yen, J. J.; Dymock, B. W. Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines. J. Med. Chem. 2016, 59, 8233?8262.
2. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat Lianbin Yao, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Prachi Singh, Minh-Dao Duong-Thi, Jeannie X. T. Lee, Pondy Murugappan Ramanujulu, Wee Joo Chng, Jeffrey J. Y. Yen, Sten Ohlson, and Brian W. Dymock Publication Date (Web): September 27, 2017 (Article) doi: 10.1021/acs.jmedchem.7b00678